US/UK/Germany/Switzerland/Israel
Current study: BR-003 Clinical Trial

BR-003: Prospective, Multicenter Confirmatory Clinical Evaluation of Novilase® Interstitial Laser Therapy for the Focal Destruction of Malignant Breast Tumors ≤15 mm

www.ClinicalTrials.gov : NCT03463954

The purpose of the BR-003 pivotal clinical trial:

BR-003 CLINICAL TRIAL SITES

The main goal of the BR-003 clinical trial is to evaluate the effectiveness of tumor ablation for early-stage breast cancers that are 15 mm or smaller in size. The trial will compare the results obtained from post-ablation MRI and ultrasound imaging with the post-excision histology results to establish correlations between them.

If you need a referral to any investigators, please get in touch with info@novianhealth.com. Sites that have already started enrolling subjects are indicated with “(enrolling).”

USA | UK | Germany | Switzerland | Israel

USA:

California:

University of California San Diego (enrolling)
La Jolla, CA

City of Hope National Cancer Center (enrolling)
Duarte, CA

Eisenhower Health (enrolling)
Rancho Mirage, CA

Connecticut:

Yale University| Yale New Haven Health Shoreline Medical Center (enrolling)
Guilford, CT

Maryland:

Walter Reed National Military Medical Center (enrolling)
Bethesda, MD

New York:

Kaleida Health |Buffalo General Medical Center (enrolling)
Buffalo, NY

New Jersey:

Summit Health (enrolling)
Florham Park, NJ

UK:

Oxford University Hospitals NHS Trust| Churchill Hospital (enrolling)
Oxford, UK

Imperial College Healthcare NHS Trust/ Charing Cross Hospital (enrolling)
London, UK

Germany:

Heidelberg University Hospital
Heidelberg

St. Elisabeth-Krankenhaus Köln-Hohenlind (enrolling)
Cologne

Switzerland:

University Hospital Zurich (enrolling)
Zurich

Israel:

Tel Aviv Sourasky Medical Center (Ichilov) (enrolling)
Tel Aviv